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Results
summarizes the baseline characteristics of the trial participants. There were no significant differences in location, age, gender, body weight, BMI or magnesium status between MagSRT™ and placebo participants.
Magnesium Absorption
Serum magnesium increased 22% four hours after taking two tablets of MagSRT™, then decreased 5% after an additional four hours ( Figure 2 ). The initial increase in serum magnesium suggests that magnesium was absorbed through the small intestine into the bloodstream. The slight decrease at 8 hours may have captured the body in the process of regulating serum magnesium concentration, either by incorporating it into cells or releasing it into the urine. Serum magnesium did not increase in those taking the placebo.
The laxative effects of magnesium are greatly diminished when magnesium is well absorbed. Ninety-one percent of trial participants completed the 30-day trial and 75% reported no side effects. Of those individuals who continued the trial for 90 days, none reported side effects.
Uptake of Magnesium into Red Blood Cells
RBC magnesium levels increased 6% and 30% over 30 and 90 days, respectively, in the MagSRT™ group. Both increases are statistically significant (p <0.001). RBC magnesium levels increased 2% in the placebo group after 30 days. Although significant (p = 0.035), it is unlikely that this increase is clinically relevant. RBC magnesium values as a function of time are summarized in Figure 3 .
Red blood cell magnesium is a better measure of magnesium stores than serum magnesium and values exceeding 6.0 mg/dL are considered optimal. 
RBC Magnesium increased by 30% with MagSRT™
and gagging/choking from esophageal spasms. These results suggest that MagSRT™ may provide a safe, highly effective clinical tool for addressing these particular symptoms. However, because the supplement contains significant amounts of methyl folate, B12 and B6 in addition to magnesium, we cannot conclude that magnesium alone is responsible for the improvement in symptomatology. A future trial evaluating the effect of dimagnesium malate alone on the magnesium status questionnaire scores is necessary to further validate the magnesium status questionnaire used in this study.
Magnesium Status
There is no recent published data on magnesium status among Americans; therefore, evaluating baseline magnesium status and the impact of magnesium supplementation on status was a secondary objective of this study. Figure 5 summarizes the change in serum and RBC magnesium status after supplementing with MagSRT™ for 30 days.
The normal range for serum magnesium is between 1.6 and 2.3 mg/dL; however, optimal serum magnesium status is expected at values ≥ 2.0 mg/dL. 4 At baseline, 17% of MagSRT™ participants had serum magnesium values ≥ 2.0 mg/ dL, indicating that 83% had suboptimal serum magnesium status. Eight hours after ingesting 250 mg of dimagnesium malate, 42% of MagSRT™ participants had serum magnesium values ≥ 2.0 mg/dL.
The normal range for RBC magnesium is between 4.2 and 6.8 mg/dL. There is some debate around optimal intracellular magnesium levels. One source suggests that an optimal RBC magnesium would be ≥ 6.0 mg/dL. 5 At baseline, 9% of MagSRT™ participants had RBC magnesium values of 6 or greater, indicating that 91% had low RBC magnesium status. After 30 days, 16% in the MagSRT™ trial had a RBC magnesium value ≥ 6 mg/dL. Of those who continued the MagSRT™ trial for 90 days, 48% reached optimal magnesium status. According to these ranges for both serum and RBC magnesium, roughly 80 -90% of this trial population may have had suboptimal magnesium status at baseline. These findings correlate well with the results from the magnesium status survey, which indicated that 100% of participants had a score ≥ 30 at baseline, suggesting low magnesium status.
Conclusion
A standard adult clinical population presented with both qualitative and quantitative evidence of compromised magnesium status at the beginning of the trial. Supplementation with MagSRT™ for at least 30 days significantly improved magnesium status symptoms and increased RBC magnesium with minimal gastrointestinal symptoms.
